about
8-Substituted O(6)-cyclohexylmethylguanine CDK2 inhibitors: using structure-based inhibitor design to optimize an alternative binding modeA new tool for the chemical genetic investigation of the Plasmodium falciparum Pfnek-2 NIMA-related kinaseDesign and synthesis of biphenyl and biphenyl ether inhibitors of sulfatases.Identification and Characterization of an Irreversible Inhibitor of CDK2.Structure-guided design of purine-based probes for selective Nek2 inhibitionCombined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancerTargeting DNA-Dependent Protein Kinase for Cancer Therapy.Structural insights into the enzymatic activity and potential substrate promiscuity of human 3-phosphoglycerate dehydrogenase (PHGDH).Human Toxicity Caused by Indole and Indazole Carboxylate Synthetic Cannabinoid Receptor Agonists: From Horizon Scanning to Notification.Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines.Synthesis and Biological Evaluation of N(2) -Substituted 2,4-Diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines and Related 5-Cyano-NNO-azoxy Derivatives as Cyclin-Dependent Kinase 2 (CDK2) Inhibitors.Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach.Recent advances in CDK inhibitors for cancer therapy.Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer.FragLites-Minimal, Halogenated Fragments Displaying Pharmacophore Doublets. An Efficient Approach to Druggability Assessment and Hit Generation
P50
Q27687812-CB43DD62-732A-4D6F-BE09-AC508987A68CQ28821870-FA83A360-8704-4AA0-A1DB-C939B36AD3F9Q33814142-C322D149-0064-4211-9D6A-F3FD889D1B78Q35759866-F0DFD0E6-90C8-43CA-A3E3-504BD8D5B9BAQ36189360-4291B483-2D55-4C35-BB11-FF7E4BBDAF60Q38751569-0B6AEE86-F604-4283-8DFB-09091984AAFDQ39250742-9630BB18-AEDF-46C6-908A-43BDCDACA999Q47147345-8E625525-FFDF-493A-A82A-6EE6D7DA3AA2Q47595832-47D10D84-DD23-4C96-970B-24C1DE55C4E7Q48124327-3CCA42CB-81B0-41C1-A6B5-AC54949080B6Q48182205-8AE2D325-F13E-4610-A53F-3CDB1AD8BBB4Q52690769-B85A2DB5-F949-4909-8F3D-8CC43FC8C4DBQ54977701-4C0CAEF6-2FBE-4D1F-BAE9-DCD86210005BQ55401567-DB88D4AE-CB06-47BB-AEED-A9D01A252553Q92295393-C22276CC-AAF2-4AA1-8C35-CEB42673B50E
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Celine Cano
@ast
Celine Cano
@en
Celine Cano
@es
Celine Cano
@nl
type
label
Celine Cano
@ast
Celine Cano
@en
Celine Cano
@es
Celine Cano
@nl
prefLabel
Celine Cano
@ast
Celine Cano
@en
Celine Cano
@es
Celine Cano
@nl
P106
P1153
24480527500
P31
P496
0000-0002-2032-2272